Success Metrics

Clinical Success Rate
91.0%

Based on 111 completed trials

Completion Rate
91%(111/122)
Active Trials
7(5%)
Results Posted
59%(66 trials)
Terminated
11(7%)

Phase Distribution

Ph not_applicable
14
9%
Ph phase_4
28
18%
Ph early_phase_1
6
4%
Ph phase_2
65
42%
Ph phase_1
18
12%
Ph phase_3
21
14%

Phase Distribution

24

Early Stage

65

Mid Stage

49

Late Stage

Phase Distribution152 total trials
Early Phase 1First-in-human
6(3.9%)
Phase 1Safety & dosage
18(11.8%)
Phase 2Efficacy & side effects
65(42.8%)
Phase 3Large-scale testing
21(13.8%)
Phase 4Post-market surveillance
28(18.4%)
N/ANon-phased studies
14(9.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.8%

111 of 134 finished

Non-Completion Rate

17.2%

23 ended early

Currently Active

7

trials recruiting

Total Trials

153

all time

Status Distribution
Active(11)
Completed(111)
Terminated(23)
Other(8)

Detailed Status

Completed111
Withdrawn12
Terminated11
unknown7
Recruiting6
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
153
Active
7
Success Rate
91.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (3.9%)
Phase 118 (11.8%)
Phase 265 (42.8%)
Phase 321 (13.8%)
Phase 428 (18.4%)
N/A14 (9.2%)

Trials by Status

terminated117%
active_not_recruiting11%
unknown75%
completed11173%
not_yet_recruiting32%
withdrawn128%
enrolling_by_invitation11%
recruiting64%
suspended11%

Recent Activity

Clinical Trials (153)

Showing 20 of 153 trialsScroll for more
NCT04678895Phase 2

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

Recruiting
NCT07224009Phase 2

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Not Yet Recruiting
NCT05458609Phase 3

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep

Completed
NCT07475546Phase 3

Combination Gerotherapeutic Interventions for Healthspan Improvement

Active Not Recruiting
NCT07433413Phase 3

Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder

Not Yet Recruiting
NCT04276259Phase 4

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Completed
NCT05509257Early Phase 1

Naltrexone Neuroimaging in Teens With Eating Disorders

Recruiting
NCT04166071Early Phase 1

Opioids and Social Support Enhanced Extinction Effects

Enrolling By Invitation
NCT05968690Phase 1

Naltrexone and Propranolol Combined With Immunotherapy

Recruiting
NCT07092618Phase 2

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

Recruiting
NCT02330419Phase 2

Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)

Completed
NCT01950520Phase 2

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Completed
NCT06622239Phase 2

Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury

Not Yet Recruiting
NCT06426303Phase 4

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

Recruiting
NCT04450316Phase 2

Low-dose Naltrexone for Bladder Pain Syndrome

Suspended
NCT00439049

Substance Abuse Pre-Treatment Screening Study

Recruiting
NCT04854551Phase 1

Opioid Modulation and Neural Reward Activation in Healthy Adults

Completed
NCT02885311Phase 1

Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home

Completed
NCT04935931Early Phase 1

Naltrexone Neuroimaging

Completed
NCT04249882Phase 2

A Novel Human Lab Model for Screening AUD Medications

Completed

Drug Details

Intervention Type
DRUG
Total Trials
153